Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Semaglutide 0.68 mg/mL vs 1.34 mg/mL
NCT05689099Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the concentration-time curve from time 0 to last quantifiable measurement and Maximum observed concentration. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05689099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689099.